Qiagen N.V. (QGEN) : 12 analysts are covering Qiagen N.V. (QGEN) and their average rating on the stock is 2.63, which is read as a Hold. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Qiagen N.V. (QGEN) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. 1 more analyst has given the stock a Sell recommendation. A total of 8 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Qiagen N.V. (QGEN) : Currently there are 7 street experts covering Qiagen N.V. (QGEN) stock. The most bullish and bearish price target for the stock is $27 and $22 respectively for the short term. The average price target of all the analysts comes to $25. The estimated standard deviation from the target is $1.91.
Company shares have received an average consensus rating of Hold for the current week Qiagen N.V. (NASDAQ:QGEN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $26.85 and $26.70 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $26.93. The buying momentum continued till the end and the stock did not give up its gains. It closed at $26.75, notching a gain of 0.45% for the day. The total traded volume was 879,035 . The stock had closed at $26.63 on the previous day.
QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.